The Remarkable Selectivity of Nirmatrelvir.
The Remarkable Selectivity of Nirmatrelvir.
复制标题
DOI：
10.1021/acsptsci.2c00065
复制
发表时间：
2022-06-10
影响因子：
--
通讯作者：
Thomas, Craig J
中科院分区：
文献类型：
--
作者：
Duveau, Damien Y;Thomas, Craig J
The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 Mpro but also minimal polypharmacology versus human cysteine proteases. This Viewpoint explores the activity profile of the first approved SARS-CoV-2 Mpro inhibitor (Nirmatrelvir) versus a panel of cysteine proteases and considers the therapeutic implications of the data.
